Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14010 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Hans-Juergen Laws und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf,…. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Objective
To assess the impact of prophylaxis with rIX‐FP, a fusion protein linking recombinant factor IX (FIX) with human albumin, on joint outcomes.
Methods
Joint outcomes were assessed in pediatric (18 years) well‐controlled on a 14‐day regimen could switch to a 21‐day regimen. Target joints were defined as ≥3 spontaneous bleeds into a single joint within a 6‐month period.
Results
For adult/adolescent ( n = 63) and pediatric ( n = 27) patients, median (Q1, Q3) annualized joint bleeding rate was 0.39 (0.00, 2.31), 0.80 (0.00, 2.85), 0.20 (0.00, 2.58), and 0.00 (0.00, 1.78) when treated with 7‐, 10‐, 14‐, or 21‐day prophylaxis. 50.0%, 38.9%, 45.5%, and 63.6% of adult/adolescent patients had no joint bleeds when treated with 7‐, 10‐, 14‐, or 21‐day prophylaxis, respectively, and 40.7%, 37.5%, and 37.5% of pediatric patients had no joint bleeds when treated with 7‐, 10‐, or 14‐day prophylaxis. Ten adult and two pediatric patients developed target joints; all resolved by the end of the study.
Conclusion
Prophylaxis with rIX‐FP produced low joint bleeding rates and provided excellent hemostatic efficacy in the treatment of joint bleeds. All target joints reported resolved with rIX‐FP prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf, Germany.
- Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
- Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
- Haematology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
- CSL Behring, King of Prussia, Pennsylvania, USA.
- Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy.
Förderung
- CSL Behring
Zitieren
APA
Laws, H. J., Fukutake, K., Lopez-Fernandez, M. F., Li, Y., Seifert, W., & Tagliaferri, A. (2023). Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program. European Journal of Haematology. https://doi.org/10.1111/ejh.14010
Vancouver
Laws HJ, Fukutake K, Lopez-Fernandez MF, Li Y, Seifert W, Tagliaferri A. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program. European Journal of Haematology. 2023. doi:10.1111/ejh.14010
BibTeX
@article{Laws2023,
author = {Laws, Hans-Juergen and Fukutake, Katsuyuki and Lopez-Fernandez, Maria Fernanda and Li, Yanyan and Seifert, Wilfried and Tagliaferri, Annarita},
title = {Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14010}
}
EUVIMED